{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:39:58Z","timestamp":1792773598408,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009242","name":"Direction g\u00e9n\u00e9rale de l'offre de soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PHRC-K 2019 Inca-DGOS_14333"],"award-info":[{"award-number":["PHRC-K 2019 Inca-DGOS_14333"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PRT-K 2020-15324"],"award-info":[{"award-number":["PRT-K 2020-15324"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["INCa-DGOS-INSERM-ITMO cancer_18003"],"award-info":[{"award-number":["INCa-DGOS-INSERM-ITMO cancer_18003"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016912","name":"MSD France SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108343","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:35:05Z","timestamp":1788989705000},"page":"108343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR\/MSI esophagogastric cancers? Results from the IMHOTEP phase II study"],"prefix":"10.1016","volume":"11","author":[{"given":"C.","family":"Coutzac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-5653","authenticated-orcid":false,"given":"A.","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-2385","authenticated-orcid":false,"given":"A.","family":"de Montfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Soularue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-5162","authenticated-orcid":false,"given":"R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Le Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Piessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-6448","authenticated-orcid":false,"given":"V.","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-6346","authenticated-orcid":false,"given":"M.","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Svrcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6997-6090","authenticated-orcid":false,"given":"E.","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-7419","authenticated-orcid":false,"given":"D.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"C.","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7517","key":"10.1016\/j.esmoop.2026.108343_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108343_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2026.108343_bib3","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6349","key":"10.1016\/j.esmoop.2026.108343_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108343_bib5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108343_bib6","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108343_bib7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108343_bib8","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.108343_bib9","article-title":"NEOPRISM-CRC: neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer","volume":"42","author":"Shiu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108343_bib10","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2024.08.1514","article-title":"1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI localized cancers: results of the digestive non-colorectal cancer cohorts","volume":"35","author":"de la Fouchardi\u00e8re","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108343_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108343_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108343_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.dld.2022.07.008","article-title":"Immunotherapy in MSI\/dMMR tumors in the perioperative setting: the IMHOTEP trial","volume":"54","author":"Coutzac","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108343_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMc2409154","article-title":"The duration of immunotherapy for mismatch repair-deficient cancers","volume":"392","author":"Rousseau","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108343_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2026.108343_bib16","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO-25-00447","article-title":"Neoadjuvant CTLA-4\/PD-(L)1 blockade versus surgery +\/- chemotherapy in deficient mismatch repair\/microsatellite instability-high resectable gastroesophageal adenocarcinoma: individual patient data pooled analysis","volume":"43","author":"Raimondi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108343_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1200\/JCO-25-02169","article-title":"Efficacy of perioperative pembrolizumab in mismatch repair deficient\/microsatellite unstable localized colorectal cancers: results of the phase II trial IMHOTEP","volume":"44","author":"de la Fouchardi\u00e8re","year":"2026","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108343_bib18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","article-title":"Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer","volume":"394","author":"Sinicrope","year":"2026","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108343_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.esmoop.2026.108343_bib20","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108343_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:40:53Z","timestamp":1792770053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926022854"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108343","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR\/MSI esophagogastric cancers? Results from the IMHOTEP phase II study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108343"}}